Search - tctmd.com

Displaying 1 - 20 of 50

Sort: Relevancy | Date

News Conference News AHA 2017

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

Todd Neale

November 22, 2017

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

Todd Neale

November 16, 2017

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

News Conference News TCT 2017

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

Todd Neale

November 02, 2017

Presentation TCT 2017

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Pascal Vranckx

November 01, 2017

Presentation TCT 2017

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Renato D. Lopes

November 01, 2017

Presentation TCT 2017

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2017

Optimizing the Acute and Chronic Use of Antiplatelet and Antithrombotic Agents (and Their Combination): 2017 Update

Presenter: Debabrata Mukherjee, E. Murat Tuzcu, Dimitrios Alexopoulos

November 01, 2017

Presentation TCT 2017

Antithrombotic Therapy Considerations After TMVR: What Can We Learn From the Surgical Experience?

Presenter: Vinayak Bapat, Maurice Buchbinder

October 31, 2017

Presentation TCT 2017

TCT 91: Antithrombotic Therapy Post Transcatheter Aortic Valve Replacement in Patients With No Indication for Anticoagulation

Presenter: Kurt Huber, Jamil Abdalla Saad, Dimitrios Alexopoulos, Antonio L. Bartorelli, Bjorn Redfors, Carlos E. Uribe

October 31, 2017

Presentation TCT 2017

Case Comments: What Antithrombotic/Antiplatelet Regimen Should We Start?

Presenter: Nick Curzen, Rod H. Stables, Alexey Protopopov

October 31, 2017

News Daily News

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Yael L. Maxwell

October 23, 2017

News Daily News

Blood in Urine Carries Consequences for Patients on Antithrombotics

Yael L. Maxwell

October 09, 2017

Presentation

Association Between Use of Antithrombotic Medication and Hematuria-Related Complications

October 09, 2017

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

News Daily News

Stroke, Bleeding Risks High in A-fib Patients With Contraindications to Anticoagulation

Todd Neale

September 27, 2017

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Daily News

Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib

Todd Neale

September 14, 2017

News Conference News ESC 2017

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

Todd Neale

September 01, 2017

Advertisement

‘Acceptable Safety’ for LAA Closure Seen in a Real-World, All-Comers Registry

RE-DUAL PCI Findings Consistent Across Key Subgroups

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation - Are the Results Enough to Change Practice?

Optimizing the Acute and Chronic Use of Antiplatelet and Antithrombotic Agents (and Their Combination): 2017 Update

Antithrombotic Therapy Considerations After TMVR: What Can We Learn From the Surgical Experience?

TCT 91: Antithrombotic Therapy Post Transcatheter Aortic Valve Replacement in Patients With No Indication for Anticoagulation

Case Comments: What Antithrombotic/Antiplatelet Regimen Should We Start?

Lesion Complexity and Patient Risk: A Balancing Act for DAPT Duration

Blood in Urine Carries Consequences for Patients on Antithrombotics

Association Between Use of Antithrombotic Medication and Hematuria-Related Complications

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Stroke, Bleeding Risks High in A-fib Patients With Contraindications to Anticoagulation

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Rivaroxaban, Warfarin Provide Similar Results Early After Mild Strokes Related to A-fib

ESC Releases Revamped DAPT Guidance Focusing on Personalized Approach

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content